PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER
- 1 November 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (5) , 1538-1542
- https://doi.org/10.1016/s0022-5347(05)67023-1
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Phase II Study of Cisplatin and Paclitaxel in Advanced Carcinoma of the Urothelium: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of Clinical Oncology, 1991
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of Clinical Oncology, 1990
- Confidence Intervals for a Binomial Parameter Based on Multistage TestsBiometrics, 1987
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958